← All diseases

Blood and immune system diseases

X-linked agammaglobulinemia (Bruton disease)

An inherited immunodeficiency in which the body cannot make antibodies. It almost always affects males. Frequent and repeated bacterial infections occur.

Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source

Orphanet has a guideline for emergency doctors for this disease (language: French). See on Orphanet

Prepare an emergency card

This page is translated from the Turkish original.

This disease is followed through the “Blood and immune system diseases” group.

Understanding the disease

This section has not yet been reviewed by a physician. It summarises patient information from sources such as MedlinePlus, Orphanet and the NHS in plain language. The disease can differ from person to person; talk to your doctor about diagnosis and treatment.

What happens in this disease?

B cells are white blood cells that make antibodies. Antibodies mark germs so that they can be destroyed. In this disease, the BTK gene is faulty, so B cells cannot develop. The body makes very few antibodies and becomes open to infections.

Which symptoms can occur?

Babies are protected for the first 1-2 months by antibodies passed on from the mother. Then repeated infections begin.

  • Pneumonia and bronchitis (common)
  • Ear and sinus infections (common)
  • Eye infections (common)
  • Long-lasting diarrhea
  • Infections that heal slowly and come back often
  • Swelling and pain in the joints
  • Some viral infections being severe

How is it diagnosed?

Antibody levels in the blood are measured, and all are found to be very low. The number of B cells in the blood is checked; there are very few B cells. The diagnosis is confirmed with a genetic test showing the change in the BTK gene.

Treatment and care

The main treatment is regularly replacing the missing antibodies. This treatment is given through a vein or under the skin. It reduces infections and improves quality of life. Infections are treated with antibiotics. Sometimes preventive antibiotics are also given. The doctor who follows the disease decides which treatment is suitable.

For the family: inheritance and genetic counselling

The disease is passed on through X-linked recessive inheritance and almost always affects males. A mother who is a carrier has a 1 in 4 chance of having an affected boy in each pregnancy. Women who are carriers have no immune problems. All daughters of an affected father become carriers, while his sons are not affected. In about half of patients, no one else in the family is affected. Genetic counselling guides the family.

Source: MedlinePlus Genetics: X-linked agammaglobulinemia · NORD: Agammaglobulinemias, Primary

Key facts

How common is it?
Prevalence: 1-9 per 1 000 000 (Worldwide)
How is it inherited?
X-linked recessive
When does it usually start?
Childhood
Gene(s) involved
BTK

These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.

You are not alone: patient associations in Türkiye

Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.

We could not find a patient association specific to this disease.

For all rare diseases: Nadir Hastalıklar Federasyonu

Support and help

Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.

News about XLA (Bruton)

Clinical trials (ClinicalTrials.gov)

A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.

This list is not a treatment recommendation. Treatments tested in phase 1–3 trials are investigational (experimental): their efficacy and safety have not yet been proven and they are not approved treatments. Taking part depends on each trial’s criteria and a physician’s assessment; the first step is to talk to the doctor who manages your care.

Questions you can ask your doctor

  • Could this trial be suitable for us?
  • If we take part, how would current treatment and check-ups be affected?
  • Where does the trial take place, and how are travel and accommodation handled?
  • What happens if we want to leave the trial?

ClinicalTrials.gov lists 2 active interventional studies for this disease. 1 is recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.

Selected records (studies with a site in Türkiye first):

See all studies on ClinicalTrials.gov · Joining clinical trials

Blood and immune system diseases: other news

Medical codes (for talking with your doctor and finding sources)

These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.

Orphanet code: ORPHA:47

No separate ICD-11 code; WHO classifies this disease under: 4A01.00

Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.

This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.

The information on these pages is for general information only and does not replace medical advice. Talk to your doctor about diagnosis and treatment decisions. In an emergency in Türkiye, call 112.

Every update is based on an open source and labeled with its level of evidence. No advertising and no drug brand names. Our scientific principles

This page was translated from Turkish by the Doktorclub editorial team.